From Idea to Impact: Prioritizing the Risks That Matter Most

Early-stage medtech companies face a constant challenge: too many priorities, limited resources, and a long path from concept to clinical impact. In a MedTech Summit talk hosted by MedTech Connect, Nathan Friedman, CEO and Co-founder of HemaSense, shared the framework HemaSense uses to prioritize development work and focus on the risks that matter most.

The talk, “From Idea to Impact,” draws on Nathan’s experience in large-company medical device development, startup company building, and the early development of HemaSense’s wearable monitoring technology for post-procedure bleeding detection. Rather than treating every open question as equally urgent, the framework separates uncertainty into three categories: technical risk, market and adoption risk, and business and execution risk.

For HemaSense, that approach has meant focusing early resources on the areas that could most directly determine whether the company can succeed. As Nathan describes in the talk, the team prioritized the skin interface and electrode configuration before over-investing in electronics, because high-quality patient data was the critical enabling requirement. The electronics, communication systems, and data-processing components could then be built around a de-risked signal acquisition strategy.

The same discipline applies beyond engineering. The talk also highlights the importance of understanding clinical workflow, hospital adoption dynamics, health economics, regulatory strategy, and investor expectations. In early-stage medtech, the company is not only developing a product for clinicians and patients; it is also building a credible investment opportunity that can support the long development timelines required in regulated healthcare markets.

At HemaSense, this risk-first approach helps guide how the team allocates time, capital, and attention. The goal is not simply to move quickly, but to move efficiently: identifying the uncertainties that could meaningfully change the company’s trajectory, addressing them directly, and using those answers to inform the next phase of development.